These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

390 related articles for article (PubMed ID: 24667589)

  • 1. Mucosal healing with thalidomide in refractory Crohn's disease patients intolerant of anti-TNF-α drugs: report of 3 cases and literature review.
    Scribano ML; Cantoro L; Marrollo M; Cosintino R; Kohn A
    J Clin Gastroenterol; 2014 Jul; 48(6):530-3. PubMed ID: 24667589
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Certolizumab pegol for the management of Crohn's disease in adults.
    Rivkin A
    Clin Ther; 2009 Jun; 31(6):1158-76. PubMed ID: 19695385
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Management of inflammatory bowel disease with infliximab and other anti-tumor necrosis factor alpha therapies.
    Magro F; Portela F
    BioDrugs; 2010 Dec; 24 Suppl 1():3-14. PubMed ID: 21175228
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mucosal healing at 3 months predicts long-term endoscopic remission in anti-TNF-treated luminal Crohn's disease.
    af Björkesten CG; Nieminen U; Sipponen T; Turunen U; Arkkila P; Färkkilä M
    Scand J Gastroenterol; 2013 May; 48(5):543-51. PubMed ID: 23477356
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organization: when to start, when to stop, which drug to choose, and how to predict response?
    D'Haens GR; Panaccione R; Higgins PD; Vermeire S; Gassull M; Chowers Y; Hanauer SB; Herfarth H; Hommes DW; Kamm M; Löfberg R; Quary A; Sands B; Sood A; Watermeyer G; Lashner B; Lémann M; Plevy S; Reinisch W; Schreiber S; Siegel C; Targan S; Watanabe M; Feagan B; Sandborn WJ; Colombel JF; Travis S
    Am J Gastroenterol; 2011 Feb; 106(2):199-212; quiz 213. PubMed ID: 21045814
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Certolizumab pegol: a TNF-{alpha} antagonist for the treatment of moderate-to-severe Crohn's disease.
    Smith LS; Nelson M; Dolder CR
    Ann Pharmacother; 2010 Feb; 44(2):333-42. PubMed ID: 20118143
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Effectiveness of anti-TNF alpha antibodies in treatment of fistulizing Crohn's disease].
    Rozpondek P; Zwolińska-Wcisło M; Przybylska M; Mach T
    Przegl Lek; 2011; 68(9):602-5. PubMed ID: 22335009
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Certolizumab pegol: new drug. As a last resort in Crohn's disease: continue to use other TNF alpha inhibitors.
    Prescrire Int; 2009 Jun; 18(101):108-10. PubMed ID: 19637418
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transcending conventional therapies: the role of biologic and other novel therapies.
    Sandborn WJ
    Inflamm Bowel Dis; 2001 May; 7 Suppl 1():S9-16. PubMed ID: 11380043
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Thalidomide use and outcomes in pediatric patients with Crohn disease refractory to infliximab and adalimumab.
    Felipez LM; Gokhale R; Tierney MP; Kirschner BS
    J Pediatr Gastroenterol Nutr; 2012 Jan; 54(1):28-33. PubMed ID: 21681114
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prospective evaluation of anti-tumor necrosis factor therapy guided by magnetic resonance imaging for Crohn's perineal fistulas.
    Ng SC; Plamondon S; Gupta A; Burling D; Swatton A; Vaizey CJ; Kamm MA
    Am J Gastroenterol; 2009 Dec; 104(12):2973-86. PubMed ID: 19755971
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Maintenance therapy with certolizumab pegol for Crohn's disease.
    Schreiber S; Khaliq-Kareemi M; Lawrance IC; Thomsen OØ; Hanauer SB; McColm J; Bloomfield R; Sandborn WJ;
    N Engl J Med; 2007 Jul; 357(3):239-50. PubMed ID: 17634459
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of Infliximab in Crohn's Disease Patients with Prior Primary-Nonresponse to Tumor Necrosis Factor Antagonists.
    Clark-Snustad KD; Singla A; Lee SD
    Dig Dis Sci; 2019 Jul; 64(7):1952-1958. PubMed ID: 30815825
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mucosal healing of ileal lesions is associated with long-term clinical remission after infliximab maintenance treatment in patients with Crohn's disease.
    Beppu T; Ono Y; Matsui T; Hirai F; Yano Y; Takatsu N; Ninomiya K; Tsurumi K; Sato Y; Takahashi H; Ookado Y; Koga A; Kinjo K; Nagahama T; Hisabe T; Takaki Y; Yao K
    Dig Endosc; 2015 Jan; 27(1):73-81. PubMed ID: 24833527
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An open-label study of thalidomide for maintenance therapy in responders to infliximab in chronically active and fistulizing refractory Crohn's disease.
    Sabate JM; Villarejo J; Lemann M; Bonnet J; Allez M; Modigliani R
    Aliment Pharmacol Ther; 2002 Jun; 16(6):1117-24. PubMed ID: 12030953
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mucosal healing in pediatric Crohn's disease after anti-TNF therapy: a long-term experience at a single center.
    Nobile S; Gionchetti P; Rizzello F; Calabrese C; Campieri M
    Eur J Gastroenterol Hepatol; 2014 Apr; 26(4):458-65. PubMed ID: 24445727
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Anti-TNF therapy in treatment of luminal Crohn's disease].
    Marko B; Prka L
    Acta Med Croatica; 2013 Apr; 67(2):179-89. PubMed ID: 24471301
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Thalidomide induces mucosal healing in Crohn's disease: case report.
    Leite MR; Santos SS; Lyra AC; Mota J; Santana GO
    World J Gastroenterol; 2011 Dec; 17(45):5028-31. PubMed ID: 22174554
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Concomitant therapy with methotrexate and anti-TNF-α in pediatric patients with refractory crohn's colitis: a case series.
    Absah I; Faubion WA
    Inflamm Bowel Dis; 2012 Aug; 18(8):1488-92. PubMed ID: 21882301
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Optimizing anti-TNF treatment in inflammatory bowel disease.
    Rutgeerts P; Van Assche G; Vermeire S
    Gastroenterology; 2004 May; 126(6):1593-610. PubMed ID: 15168370
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.